Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model

Value in Health

Volumn 12, Issue 2, 2009, Pages 226-233

  Sander, Beate ^a,b,c   Nizam, Azhar ^d   Garrison Jr , Louis P ^e   Postma, Maarten J ^f   Halloran, M Elizabeth ^e   Longini Jr , Ira M ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Computer simulation; Cost benefit analysis; Economics; Human disease outbreaks; Influenza; Pharmaceutical models; Theoretical

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; INFLUENZA; MORTALITY; OUTCOME ASSESSMENT; PANDEMIC; PRIORITY JOURNAL; QUALITY OF LIFE; STOCHASTIC MODEL; UNITED STATES; VACCINATION; BIOLOGICAL MODEL; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE OUTBREAKS; ECONOMICS; INFLUENZA, HUMAN; PROCEDURES; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; STATISTICS;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; MODELS, ECONOMIC; PUBLIC HEALTH; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; STOCHASTIC PROCESSES; UNITED STATES;

EID: 60349094121     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00437.x     Document Type: Article

References (37)

1. Germann TC, Kadau K, Longini IM Jr., Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006 103 : 5935 40.
2. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006 442 : 448 52.
3. Halloran ME, Ferguson NM, Eubank S, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci USA 2008 105 : 4639 44.
4. US Department of Health and Human Services. HHS pandemic influenza plan [monograph on the Internet]. Washington; 2005. Available from: http://www.hhs.gov/pandemicflu/plan/ [Accessed July 2, 2007].
5. Committee on Modeling Community Containment for Pandemic Influenza. Modeling community containing pandemic influenza: a letter report 2006 [monograph on the Internet]. Washington, The National Academies Press; 2006. Available from: http://www.nap.edu/catalog/11800.html [Accessed July 2, 2007].
6. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999 18 : 3263 82.
7. Longini IM Jr., Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004 159 : 623 33.
8. Halloran ME, Longini IM, Cowart DM, Nizam A. Community interventions and the epidemic prevention potential. Vaccine 2002 20 : 3254 62.
9. Elveback LR, Fox JP, Ackerman E, et al. An influenza simulation model for immunization studies. Am J Epidemiol 1976 103 : 152 65.
10. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005 23 : 1284 93.
11. Halloran ME, Hayden FG, Yang Y, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007 165 : 212 21.
12. Longini IM, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005 309 : 1083 7.
13. Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol 1990 28 : 365 82.
14. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000 343 : 1282 9.
15. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001 285 : 748 54.
16. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999 341 : 1336 43.
17. Yang Y, Longini IM, Halloran ME. Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. Appl Stat 2006 55 : 317 30.
18. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003 163 : 1667 72.
19. Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000 19 : 834 42.
20. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004 432 : 904 6.
21. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003 7 : 1 170.
22. Bettis R, Iacuzio D, Jung T, et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig 2006 26 : 329 40.
23. Sander B, Gyldmark M, Aultman R, Aoki FY. Impact on health outcomes and costs of influenza treatment with oseltamivir in elderly and high-risk patients. J Med Econ 2004 7 : 67 83.
24. Denis M. Pandemic vaccines: development status [abstract]. Presented at: Pandemic Influenza Vaccines. Building a Platform for Global Collaboration, January 28-30, 2007, Beijing, China.
25. Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes 2005 3 : 17.
26. Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004 113 : 283 90.
27. Gold MR, Siegel JR, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
28. Nettleman MD, White T, Lavoie S, Chafin C. School absenteeism, parental work loss, and acceptance of childhood influenza vaccination. Am J Med Sci 2001 321 : 178 80.
29. Rothberg MB, Fisher D, Kelly B, Rose DN. Management of influenza symptoms in healthy children: cost effectiveness of rapid testing and antiviral therapy. Arch Pediatr Adolesc Med 2005 159 : 1055 62.
30. US Department of Education Institute of Education Sciences; National Center for Educations Statistics. Digest of education statistics 2005. Available from: http://nces.ed.gov/programs/digest/d05/tables/dt05-001.asp?referrer=list [Accessed November 7, 2006].
31. Physicians Desk Reference. Red Book: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale : PDR Thomson, 2006.
32. OANDA. FxConverter - Currency Converter for 164 Currencies. The Currency Site. 2006. Available from: http://www.oanda.com/ [Accessed July 5, 2006].
33. Schulpher M. The role and estimation of productivity costs in economic evaluation. In : Drummond M, ed., Economic Evaluation in Health Care: Merging Theory with Practice. New York : Oxford University Press, 2001.
34. US Department of Labor: Bureau of Labor Statistics. Compensation cost trends 2006. Available from: http://www.bls.gov/ncs/ect/home.htm [Accessed November 7, 2006].
35. US Department of Education Institute of Education Sciences; National Center for Educations Statistics. Projections of education statistics to 2015. Available from: http://nces.ed.gov/programs/projections/ [Accessed November 7, 2006].
36. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004 190 : 1627 30.
37. Congressional Budget Office. A potential influenza pandemic: an update on possible macroeconomic effects and policy issues. 2006. Available from: http://www.cbo.gov/showdoc.cfm?index=7214&sequence=0 [Accessed November 7, 2006].